Comparative effectiveness and safety of anticoagulants for the treatment of heparin-induced thrombocytopenia.
Journal
American journal of hematology
ISSN: 1096-8652
Titre abrégé: Am J Hematol
Pays: United States
ID NLM: 7610369
Informations de publication
Date de publication:
01 07 2021
01 07 2021
Historique:
received:
10
04
2021
accepted:
12
04
2021
pubmed:
16
4
2021
medline:
29
6
2021
entrez:
15
4
2021
Statut:
ppublish
Résumé
The effectiveness and safety of non-heparin anticoagulants for the treatment of heparin-induced thrombocytopenia (HIT) are not fully established, and the optimal treatment strategy is unknown. In a systematic review and meta-analysis, we aimed to determine precise rates of platelet recovery, new or progressive thromboembolism (TE), major bleeding, and death for all non-heparin anticoagulants and to study potential sources of variability. Following a detailed protocol (PROSPERO: CRD42020219027), EMBASE and Medline were searched for all studies reporting clinical outcomes of patients treated with non-heparin anticoagulants (argatroban, danaparoid, fondaparinux, direct oral anticoagulants [DOAC], bivalirudin, and other hirudins) for acute HIT. Proportions of patients with the outcomes of interest were pooled using a random-effects model for each drug. The influence of the patient population, the diagnostic test used, the study design, and the type of article was assessed. Out of 3194 articles screened, 92 studies with 119 treatment groups describing 4698 patients were included. The pooled rates of platelet recovery ranged from 74% (bivalirudin) to 99% (fondaparinux), TE from 1% (fondaparinux) to 7% (danaparoid), major bleeding from 1% (DOAC) to 14% (bivalirudin), and death from 7% (fondaparinux) to 19% (bivalirudin). Confidence intervals were mostly overlapping, and results were not influenced by patient population, diagnostic test used, study design, or type of article. Effectiveness and safety outcomes were similar among various anticoagulants, and significant factors affecting these outcomes were not identified. These findings support fondaparinux and DOACs as viable alternatives to conventional anticoagulants for treatment of acute HIT in clinical practice.
Sections du résumé
BACKGROUND
The effectiveness and safety of non-heparin anticoagulants for the treatment of heparin-induced thrombocytopenia (HIT) are not fully established, and the optimal treatment strategy is unknown. In a systematic review and meta-analysis, we aimed to determine precise rates of platelet recovery, new or progressive thromboembolism (TE), major bleeding, and death for all non-heparin anticoagulants and to study potential sources of variability.
METHODS
Following a detailed protocol (PROSPERO: CRD42020219027), EMBASE and Medline were searched for all studies reporting clinical outcomes of patients treated with non-heparin anticoagulants (argatroban, danaparoid, fondaparinux, direct oral anticoagulants [DOAC], bivalirudin, and other hirudins) for acute HIT. Proportions of patients with the outcomes of interest were pooled using a random-effects model for each drug. The influence of the patient population, the diagnostic test used, the study design, and the type of article was assessed.
RESULTS
Out of 3194 articles screened, 92 studies with 119 treatment groups describing 4698 patients were included. The pooled rates of platelet recovery ranged from 74% (bivalirudin) to 99% (fondaparinux), TE from 1% (fondaparinux) to 7% (danaparoid), major bleeding from 1% (DOAC) to 14% (bivalirudin), and death from 7% (fondaparinux) to 19% (bivalirudin). Confidence intervals were mostly overlapping, and results were not influenced by patient population, diagnostic test used, study design, or type of article.
DISCUSSION
Effectiveness and safety outcomes were similar among various anticoagulants, and significant factors affecting these outcomes were not identified. These findings support fondaparinux and DOACs as viable alternatives to conventional anticoagulants for treatment of acute HIT in clinical practice.
Identifiants
pubmed: 33857342
doi: 10.1002/ajh.26194
pmc: PMC8252596
doi:
Substances chimiques
Anticoagulants
0
Heparin
9005-49-6
Types de publication
Comparative Study
Journal Article
Meta-Analysis
Systematic Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
805-815Informations de copyright
© 2021 The Authors. American Journal of Hematology published by Wiley Periodicals LLC.
Références
Kidney Int Suppl. 1999 Nov;(72):S46-50
pubmed: 10560805
J Res Pharm Pract. 2015 Apr-Jun;4(2):73-8
pubmed: 25984544
J Vasc Surg. 2001 Jul;34(1):17-20
pubmed: 11436069
J Pharm Pract. 2021 Aug;34(4):529-534
pubmed: 31645190
Br J Haematol. 1999 Jul;106(1):195-201
pubmed: 10444187
J Thromb Haemost. 2011 Dec;9(12):2389-96
pubmed: 21883878
Nephron Clin Pract. 2006;104(4):c143-8
pubmed: 16902310
J Thromb Thrombolysis. 2012 Jan;33(1):124-8
pubmed: 21918906
Acute Med Surg. 2015 May 28;3(1):46-49
pubmed: 29123749
J Thromb Thrombolysis. 2010 Oct;30(3):276-80
pubmed: 20449633
Pharmacoeconomics. 2007;25(11):949-61
pubmed: 17960953
Thromb Haemost. 2008 Jan;99(1):208-14
pubmed: 18217156
Int J Hematol. 2017 Oct;106(4):476-483
pubmed: 28600720
Postgrad Med J. 2007 Sep;83(983):575-82
pubmed: 17823223
Res Synth Methods. 2019 Sep;10(3):476-483
pubmed: 30945438
J Womens Health (Larchmt). 2007 Jul-Aug;16(6):895-901
pubmed: 17678460
Pharmacotherapy. 2009 Sep;29(9):1073-81
pubmed: 19698012
Thromb Haemost. 2001 Jun;85(6):950-7
pubmed: 11434701
Chest. 2006 Jun;129(6):1407-16
pubmed: 16778256
Artif Organs. 2007 Jun;31(6):461-5
pubmed: 17537058
Semin Thromb Hemost. 2011 Sep;37(6):653-63
pubmed: 22102268
Arch Intern Med. 2004 Oct 11;164(18):1961-4
pubmed: 15477429
Ann Hematol. 2018 Nov;97(11):2055-2059
pubmed: 30003318
Blood. 2009 Mar 12;113(11):2402-9
pubmed: 19059879
Evid Based Ment Health. 2019 Nov;22(4):153-160
pubmed: 31563865
Thromb Res. 2006;117(5):507-15
pubmed: 15907979
Int Angiol. 2020 Feb;39(1):76-81
pubmed: 31782283
Thromb J. 2008 Jul 02;6:9
pubmed: 18597693
J Cardiothorac Surg. 2015 Feb 07;10:19
pubmed: 25879883
N Engl J Med. 2015 Jul 16;373(3):252-61
pubmed: 26176382
Crit Care. 2015 Nov 11;19:396
pubmed: 26556106
Semin Thromb Hemost. 2015 Feb;41(1):49-60
pubmed: 25590528
J Thromb Haemost. 2016 Jun;14(6):1206-10
pubmed: 27061271
Therapie. 1997 Nov-Dec;52(6):591-7
pubmed: 9734113
Thromb Res. 2015 Apr;135(4):607-9
pubmed: 25613925
J Thromb Haemost. 2014 Jul;12(7):1044-53
pubmed: 24766902
Ann Hematol. 2017 Mar;96(3):525-527
pubmed: 27822611
Intensive Care Med. 2004 Oct;30(10):1927-34
pubmed: 15156309
Harefuah. 2019 Mar;158(3):160-164
pubmed: 30916501
J Intensive Care Med. 2008 Sep-Oct;23(5):313-20
pubmed: 18701526
Blood Adv. 2018 Nov 27;2(22):3360-3392
pubmed: 30482768
Pharmacotherapy. 2008 Sep;28(9):1115-24
pubmed: 18752382
Acta Paediatr. 2001 Jul;90(7):765-71
pubmed: 11519979
Cardiovasc Hematol Agents Med Chem. 2015;13(2):82-6
pubmed: 26362274
J Thromb Thrombolysis. 2021 Apr;51(3):703-710
pubmed: 32894400
J Am Coll Cardiol. 2017 Nov 28;70(21):2636-2648
pubmed: 29169470
J Thromb Thrombolysis. 2017 Jan;43(1):79-85
pubmed: 27632140
Pediatr Blood Cancer. 2011 Jul 1;56(7):1103-9
pubmed: 21488155
J Clin Pharmacol. 2019 Jan;59(1):107-111
pubmed: 30285276
Clin Appl Thromb Hemost. 2010 Dec;16(6):663-7
pubmed: 19825921
J Pediatr. 2002 Feb;140(2):264-6
pubmed: 11865285
Am J Ther. 2011 Jan;18(1):14-22
pubmed: 21079512
ASAIO J. 2019 Feb;65(2):134-138
pubmed: 29538017
Ann Pharmacother. 2009 Jan;43(1):9-18
pubmed: 19126826
Pharmacotherapy. 2010 Dec;30(12):1229-38
pubmed: 21114390
Eur J Haematol. 2017 Oct;99(4):332-335
pubmed: 28672052
Pharmacotherapy. 2012 Jan;32(1):20-6
pubmed: 22392825
Chest. 2012 Feb;141(2 Suppl):e24S-e43S
pubmed: 22315264
Pharmacotherapy. 2005 Dec;25(12):1736-45
pubmed: 16305293
Thorac Cardiovasc Surg. 2019 Jan;67(1):21-27
pubmed: 29605959
Intern Med J. 2006 Jul;36(7):431-6
pubmed: 16780449
J Thromb Haemost. 2005 Nov;3(11):2428-36
pubmed: 16241940
Blood. 2015 Feb 5;125(6):924-9
pubmed: 25515959
Am J Hematol. 1995 Sep;50(1):20-5
pubmed: 7668220
Ann Pharmacother. 2006 May;40(5):972-6
pubmed: 16569813
Blood. 2005 Oct 15;106(8):2710-5
pubmed: 15985543
J Thorac Cardiovasc Surg. 2012 May;143(5):1213-8
pubmed: 22329977
Clin Appl Thromb Hemost. 2000 Jul;6(3):151-6
pubmed: 10898275
Res Pract Thromb Haemost. 2018 Aug 09;2(4):678-683
pubmed: 30349886
Thromb Haemost. 2001 Nov;86(5):1170-5
pubmed: 11816702
J Intensive Care Med. 2006 Mar-Apr;21(2):86-92
pubmed: 16537750
Neth J Med. 1995 Mar;46(3):146-52
pubmed: 7731489
Ann Pharmacother. 2015 Feb;49(2):178-84
pubmed: 25515865
BMJ. 2009 Jul 21;339:b2535
pubmed: 19622551
J Cardiothorac Vasc Anesth. 2014 Aug;28(4):1008-12
pubmed: 24439171
Blood. 2016 Dec 29;128(26):3043-3051
pubmed: 27793877
Thromb Haemost. 2016 Aug 1;116(2):397-400
pubmed: 27075620
Int J Clin Pharm. 2011 Dec;33(6):997-1001
pubmed: 22002684
Blood. 2006 Sep 1;108(5):1492-6
pubmed: 16690967
Am J Hematol. 2021 Jul 1;96(7):805-815
pubmed: 33857342
Clin Appl Thromb Hemost. 2001 Oct;7(4):300-4
pubmed: 11697713
Clin Appl Thromb Hemost. 2003 Jan;9(1):25-32
pubmed: 12643320
Am J Health Syst Pharm. 2015 Sep 1;72(17 Suppl 2):S104-9
pubmed: 26272889
J Clin Pharmacol. 2020 Oct;60(10):1362-1366
pubmed: 32519800
J Thromb Thrombolysis. 2009 Aug;28(2):117-23
pubmed: 18827975
Hematology. 2005 Aug;10(4):271-5
pubmed: 16085538
Blood. 2017 Aug 31;130(9):1104-1113
pubmed: 28646118
Ann Pharmacother. 2008 Mar;42(3):309-16
pubmed: 18303137
Chest. 1999 Jun;115(6):1616-20
pubmed: 10378558
Can J Hosp Pharm. 2009 Jul;62(4):290-7
pubmed: 22478907
J Cardiovasc Surg (Torino). 1999 Apr;40(2):237-42
pubmed: 10350110
Neth J Med. 2007 Mar;65(3):101-8
pubmed: 17387236
Eur J Cardiothorac Surg. 2016 Dec;50(6):1132-1138
pubmed: 27301386
J Thromb Haemost. 2005 Apr;3(4):692-4
pubmed: 15842354
Zentralbl Chir. 2001 Jan;126(1):39-43
pubmed: 11227292